文献速递白血病

PACE与OPTIC试验中慢性期慢性髓性白血病患者普纳替尼剂量调整动态

Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
PubMed 文献 · Leukemia · 2024-01-29

本研究基于PACE与OPTIC试验,分析接受普纳替尼45 mg/日治疗的慢性期慢性髓性白血病(CP-CML)患者的剂量调整动态。采用倾向性评分分析动脉闭塞事件(AOEs),发现OPTIC试验中基于反应的剂量调整策略可改善治疗耐受性并降低心血管风险。

要点

  • OPTIC试验采用基于反应的剂量递减策略,普纳替尼45 mg/日起始。
  • OPTIC中达到≤1% BCR::ABL1IS的生存率及中位时间与PACE相似或更优。
  • OPTIC患者暴露调整后的AOEs发生率低于PACE患者。

核心结论

  • 基于反应的普纳替尼给药可改善治疗耐受性并减轻心血管风险。

研究设计与样本

  • 分析PACE和OPTIC试验中接受普纳替尼45 mg/日治疗的CP-CML患者。
  • 采用倾向性评分分析评估两试验的AOEs。

主要发现

  • OPTIC中达到≤1% BCR::ABL1IS的生存率和中位时间与PACE相似或更优。
  • 两试验中T315I突变患者的结局均稳健。
  • OPTIC患者暴露调整后的AOEs发生率低于PACE患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, and induced robust and durable responses at 45 mg/day in patients with CP-CML resistant to second-generation TKIs in the PACE trial. However, cardiovascular toxicities, including arterial occlusive events (AOEs), have emerged as treatment-related AEs within this class of TKIs. The OPTIC trial evaluated the efficacy and safety of ponatinib using a novel, response-based, dose-reduction strategy in patients with CP-CML whose disease is resistant to ≥2 TKIs or who harbor T315I. To assess the dose-response relationship and the effect on the safety of ponatinib, we examined the outcomes of patients with CP-CML enrolled in PACE and OPTIC who received 45 mg/day of ponatinib. A propensity score analysis was used to evaluate AOEs across both trials. Survival rates and median time to achieve ≤1% BCR::ABL1IS in OPTIC were similar or better than in PACE. The outcomes of patients with T315I mutations were robust in both trials. Patients in OPTIC had a lower exposure-adjusted incidence of AOEs compared with those in PACE. This analysis demonstrates that response-based dosing for ponatinib improves treatment tolerance and mitigates cardiovascular risk.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jabbour E, Apperley J, Cortes J, et al. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024. PMID: 38287132. doi:10.1038/s41375-024-02159-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。